Screening for the HLA-B*5701 Allele Should Be Performed Before Prescribing TRIUMEQ 1
HLA-B*5701 screening significantly reduces the risk of an ABC hypersensitivity reaction (HSR) 2
Prospective HLA-B*5701 screening: No immunologically confirmed HSR and significant reduction of clinically suspected HSR in the PREDICT-1 study 2
![](/content/dam/global/hcpportal/master/images/homepage/products/triumeq/triumeq-hla-screening-graph.png)
Clinical description of ABC HSRs: 1
- Almost all patients developing ABC HSRs will have fever and/or rash
- Other key symptoms include: gastrointestinal, respiratory, or constitutional symptoms such as lethargy and malaise
If suspected: 1
- TRIUMEQ must be stopped without delay, even in the absence of the HLA-B*5701 allele
- After stopping treatment with TRIUMEQ for a suspected HSR, TRIUMEQ or any other medicinal product containing ABC or DTG, must never be re-initiated
- EACS and DHHS guidelines recommend screening for HLA-B*5701 before starting ABC-containing antiretroviral therapy, if not previously tested
For further information, please see the Summary of Product Characteristics.
ABC=abacavir.
DTG=dolutegravir.
EACS=European AIDS Clinical Society.
DHHS=Department of Health and Human Services.
References:
- TRIUMEQ Summary of Product Characteristics.
- Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
- European AIDS Clinical Society Guidelines, version 7.02; http://www.eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf. Updated June 2014.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Updated May 1, 2014.
TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare